No Data
No Data
12 Health Care Stocks Moving In Monday's After-Market Session
Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on "Global Transformation in Oral Medicine"
Express News | Lipella Pharmaceuticals Inc - LP-310 Shows Statistically Significant Improvements at 0.50 Mg Dose
Lipella Reports Positive Phase 2a Results From Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025
Lipella Pharmaceuticals Completes Enrollment In Phase 2a Trial Of LP-310 Liposomal Tacrolimus Oral Rinse For The Treatment Of Oral Lichen Planus (OLP)
Express News | Lipella Pharmaceuticals Inc - to Submit Ind Application for Phase 2B Trial in Late 2025